@misc{indiciae4af7a4290e4f,
  title = {Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in FLT3, TP53, and MUC4 mutations},
  author = {Gholizadeh, E. and Zangene, E. and Parsons, A. and Kontro, M. and Heckman, C. A. and Jafari, M.},
  year = {2024},
  doi = {10.1101/2024.12.31.630711},
  url = {https://www.biorxiv.org/content/10.1101/2024.12.31.630711v1},
  note = {Source identifier: 10.1101/2024.12.31.630711}
}